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INTRODUCTION 
 
Cancers of the head and neck usually refers to neoplasm arising from below the 
skull base to the region of the thoracic inlet. They are a diverse group of diseases each 
with distinct epidemiologic, anatomic and pathologic features. They show a wide variety 
in natural history, prognosis and treatment considerations (1). Head and neck cancer is an 
area of great importance to researchers and oncologists as it is related to high physical 
and psychological morbidity. 
CANCER SCENARIO 
Every year around 5 million new cases of head and neck cancers are diagnosed 
worldwide (2). Being sixth most common cancer in the world, it causes devastating effect 
on the individual by way of functional and cosmetic consequences. The incidence of head 
and neck cancers has reduced in the developed countries with the awareness that smoking 
being the commonest cause and the subsequent decrease in smokers. Global burden rises 
to 14.1 million new cases and 8.2 million cancer deaths in 2012(2A). In India, Squamous 
cell carcinoma of the head and neck is one of the commonest cancers in our country due 
to the widespread use of tobacco products in its various forms. 
Among head and neck cancers, the incidence of laryngeal cancer is (3) the most common 
and the glottic to supraglottic carcinoma ratio is approximately 3:1. 
In Tamil Nadu, MMTR states that most common cancer in men is head and neck 
cancer (19.23%) followed next  by stomach cancer (13.98%) and  lung cancer (12.46%). 
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In women, breast cancer is the most common (20.87%) followed by cervical cancer 
(11.46%), stomach cancer (8.11%) and head and neck cancer (7.53%).  
In our institute Barnard Institute of Radiology & Oncology, head and neck cancers 
constitute the majority of cases registered in our OPD, out of which laryngeal cancer is 
the third common head and neck cancer after oral cavity and oropharygeal tumors. Early 
stage laryngeal cancer is uncommon; the patient presents more commonly in the 
advanced or later stages. There is a paucity of these early staged cases, which may be due 
to lack of proper screening methods to detect early lesions or the lack of knowledge of 
the patient as well as lack of health care. Most cases present in the advanced stages and 
this can be attributed to the lack of knowledge or education of the common people about 
the causes and incidence of cancer. Only around 20 to 25% of the cases present in the 
early stages(5). Most of them belong to poor socioeconomic status, tobacco users either 
in smoked form such as cigarettes, beedis or non-smoked forms such as pan etc. 
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ANATOMY 
The larynx is often called the voice box, a name that indicates one of its functions, which 
is speaking. The other function of the larynx is to be an air passageway 
between the pharynx and the trachea(6). Air passages must be kept open at all times, and 
so the larynx is made of nine pieces of cartilage, as shown in the figure below, and is 
connected by ligaments. The cartilages are listed as below- 
Paired-     Unpaired- 
1. Arytenoids            1. Epiglottis 
2. Corniculate           2. Thyroid 
3. Cuneiform            3. Cricoid 
There are laryngeal muscles and the laryngeal membrane around which all these 
structures lie. These intrinsic muscles of the larynx are – 
1. Posterior cricoarytenoid 
2. Lateral cricoarytenoid 
3. Transverse arytenoids 
4. Thyroarytenoid 
5. Cricothyroid 
6. Vocalis 
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The larynx is subdivided into three main parts- supraglottis, glottis and subglottis.  
The supraglottis extends from the tip of the epiglottis upto the laryngeal ventricle. It is 
further made up of subsites which are namely, epiglottis, false cords, aryepiglottic folds, 
arytenoids cartilages, preepiglottic space and vestibule. 
The glottis extends from the laryngeal ventricle to an imaginary plane 1 cm below 
this level. It is made up of true vocal cords, anterior commisure and posterior commisure 
as seen in the figure below. The vocal cords located in the glottis extend from thyroid 
cartilage to the arytenoids and is basically a muscular structure, lined by mucosa. The 
anterior 3/5th of the vocal cord is called the intermembranous part which is responsible 
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for phonation. The posterior 2/5th of the vocal cord is called the inter-cartilagenous part, 
which is responsible for respiration. 
The subglottis extends from the undersurface of the true vocal cords up to the 
inferior surface of cricoids cartilage. 
 
 
 
 
Head and neck cancers of squamous cell type make up 25% of the cancer burden 
in some developing countries like India (7). Laryngeal cancer make up 2% of the total 
cancer risk, most of them being squamous cell carcinoma and its variants on histology as 
they arise from surface epithelium. Other histologies include verrucous carcinoma, small 
cell neuroendocrine tumors. Minor salivary gland tumors arise from the mucous glands in 
the supraglottic and subglottic larynx, but they are rare. Paragangliomas, carcinoids, soft-
tissue sarcomas, malignant lymphomas, and plasmacytomas are rare as well. Benign 
chondromas and osteochondromas are also reported, although rare (8). 
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RISK FACTORS 
The etiological factors of glottic cancer point to the impact that lifestyle changes in past 
century had on our health. The principle risk factors are tobacco and alcohol (9). 
TOBACCO: 
SMOKING: 
According to National Cancer Institute reports 85% of patients with head and neck 
cancers have a history of tobacco usage (10). There exists a dominant and strong 
relationship between tobacco usage and squamous cell carcinoma of the head and neck 
(SCCHN), same is true for cancer of the glottis. Development risk of SCCHN is directly 
correlated to duration and intensity of smoking (11).Smoking tobacco in the form of 
beedis, cigarettes, cigars, chutta/cheroot, dhumti, hookah and chillum is prevalent in 
India. Certain populations especially in coastal areas practice reverse smoking .About 
50% men and 11% women between 15 – 49 years of age practice smoking in India 
(12,13) 
Cigarettes are the main form of consumable tobacco worldwide.  Beedis which consist of 
a small amount of tobacco flakes wrapped in temburni leaf with a colored string at one 
end are very famous in India. The puff` rate per minute of a beedi is higher than that of an 
unfiltered cigarette which is responsible for the more carcinogenic load of beedis. 
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Nicotine is the major psycostimulant in tobacco. It increases the dopamine levels 
in nucleus accumbens and causes an incentive value and makes the habit to be repeated 
again and again causing addiction. Major carcinogens in tobacco causing cancer are PAH 
(polycyclic aromatic hydrocarbons), NNK [4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanol] and NNN (N1-nitroso nor nicotine). 
 
SMOKELESS TOBACCO: 
Globally there is a 60% increase in alternative nicotine delivery systems like snuff, 
lozenges. Betel quid is extensively used in India. It is also called as pan which consists of 
pieces of areca nut, tobacco and slaked lime. Added tothis are spices, cardamom, cloves, 
according to the local preferences and are varyingly called as gutkha, zarda, mawa, 
khaini(9) 
ALCOHOL: 
Alcohol has a synergistic effect with tobacco. Duration, intensity and 
concentration of alcohol consumption directly correlates with oral cavity cancer (14,15) 
          A meta-analysis from 26 studies of oral and pharyngeal cancers found that 
consumption of  25, 50, or 100 g pure alcohol/day was associated with a pooled relative 
risk (RR) of 1.75, 2.85, and 6.01, respectively, of oral and pharyngeal cancer(13,14) 
Alcohol consumption also leads to immunosuppression, alcohol related diseases, altered 
behavior, unhealthy dietary pattern, and unstable emotional balance. All these factors 
have impact on cancer treatment and survival.  
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HUMAN PAPILLOMA VIRUS: 
                HPV infection, although not an established cause in glottis cancer specifically, 
it is proved to be one of the causative factor in SCCHN (16). HPV prevalence is about 
30-35% observed in head and neck cancers, with HPV-16 being detected in 60- 90% of 
infected cancer cases (14, 15). HPV prevalence has been found to be highest in 
oropharynx tumors(palatine tonsil),less common in the oral cavity(17-19). 
The oncogenesis of SCCHN by HPV is by transformation of epithelial cells by viral 
oncoproteins E6 and E7 which inactivate the tumor suppressor genes p53 and Rb 
respectively in the host cell leading on to increased cell proliferation and inhibition of 
apoptosis (20-22). 
HPV positive oropharyngeal cancers have characteristic features like 
- Young patients, 
- Nonsmokers 
- Non alcoholics 
- Present with locally advanced disease with large T and N stage 
- Often with basaloid histology  
- Poorly differentiated 
-Sexually transmitted cancer due to oral sexual activity 
- Better prognosis due to sensitivity to radiotherapy and chemotherapy as   compared 
HPV negative SCCHN 
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OTHER RISK FACTORS 
Genetic susceptibility and gastroesophageal reflux, diet lacking green leafy 
vegetables, fruit and fibre are also causes for the development of laryngeal cancer. 
Occupations which expose workers to paint, gasoline fumes, asbestos and radiation are 
considered hazardous for the development of laryngeal cancer. 
 
HISTOLOGICAL CLASSIFICATION 
 
Most vocal cord carcinomas are well or moderately well differentiated. In a few 
cases, an apparent carcinoma and sarcoma occur together, but most of these are 
actually a spindle-cell carcinoma (i.e., squamous cell carcinoma with a spindle-cell 
stromal reaction). Verrucous carcinoma occurs in 1% to 2% of patients with carcinoma of 
the vocal cord. Small-cell neuroendocrine carcinoma is rarely diagnosed in the 
supraglottic larynx, but it should be recognized because of its biologic potential for rapid 
growth, early dissemination, and responsiveness to chemotherapy. 
Minor salivary gland tumors arise from the mucous glands in the supraglottic 
and subglottic larynx, but they are rare. Even rarer are paragangliomas, 
carcinoids, soft-tissue sarcomas, malignant lymphomas, and plasmacytomas. 
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SYMPTOMS 
Early stage laryngeal cancer confined to the glottis presents as hoarseness of voice 
and lesions as early as in situ lesions produce significant voice change . More advanced 
lesions present with dyspnea, stridor, hemoptysis and/ or referred otalgia. There are no 
lymphatics in the vocal cords and nodal metastasis is rarely seen unless the disease 
spreads beyond the region of the membranous cords. Therefore, these cancers are usually 
regarded to have good prognosis as they present in the early onset of the disease and 
nodal/local spread occurs late due to sparse lymphatics. 
Head and neck lodges the most crucial physiological functions like respiration, 
nutrition, language and expression most of which are unique to mankind. The oncologist 
would do well to keep in mind the possibility of preserving these functions in the 
treatment of early glottic cancer, which are amenable to preservation of the patients 
voice.  
PROGNOSTIC FACTORS 
The major determinants of prognosis are the stage of the primary lesion when 
diagnosed as well as the level of neck disease involved. Local control is more difficult in 
cases where there is increased neck disease burden. T and N stage according to AJCC(23) 
both affect Cause Specific survival as well. In general, women tend to have a better 
prognosis than men. 
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GENERAL TREAMENT OF LARYNGEAL CANCER 
Laryngeal cancers should be managed by a multi-disciplinary team comprising of 
a head and neck surgeon, a radiotherapist/ oncologist, nurse, speech and swallowing 
therapist. 
There are various treatment options for early stage glottis cancer and they include 
laser excision, endoscopic submucosal resection, partial laryngo-pharyngectomy, total 
laryngo-pharyngectomy and definitive radiotherapy (24). T1a tumors of the glottis can be 
treated effectively with laser excision. Local control and organ preservation is first 
priority in these cases and so tumors that are not controllable with these light burden 
treatment or with treatment affecting voice quality make good candidates for definitive 
radiotherapy.  
 
1. CARCINOMA IN SITU 
CIS is the replacement of the full depth of the epithelium by malignant cells, 
without the breach of the basement membrane. This stage should be considered as an 
early  lesion and should be managed as T1 carcinoma. Treatment options include trans-
oral endoscopic C02 laser and microlaryngeal cord stripping. Regular follow up is 
essential. 
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2. T1N0 
Early lesions of  glottis confined to one vocal cord is treated with either radical 
radiotherapy using a small field, measuring 4cmX4 cm, 5cmX5cm or 6cmX6cm or 
surgery using voice conservation techniques. 
Type of surgery depends on the location of the lesion. 
a. Mid-cord lesion 
i. Transoral endoscopic cordectomy/ CO2 cordectomy-  This method gives 
>90% cure rates with advantages of good voice quality preservation, very 
short treatment time and tracheostomy is avoided. 
ii. Laryngofissure with cordectomy- also produces >90% cure rates with 
slightly inferior voice quality and temporary tracheostomy is required. 
b. Cord lesion extending to the anterior commisure 
i. Radical radiotherapy 
ii. Vertical fronto-lateral laryngectomy 
iii. Endoscopic CO2 laser excision for which experience is required 
c. Pure anterior commisure lesion 
These lesions may cause early cartilage invasion and may involve base of 
epiglottis or cricothyroid membrane without causing cord fixity. Therefore, the 
possibility that T3/T4 lesions may be clinically understaged as T1/T2 cannot be 
over-looked. In these cases, cure rates will be drastically compromised if only 
radical radiotherapy is given and hence, surgery is the preferred modality. 
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4. T2N0  
These lesions include superficial tumors where vocal cords are freely mobile but 
the surface extension is beyond the glottis (T2a) or infiltrative tumors causing 
impaired cord mobility (T2b). 
a. T2a lesions- radiotherapy is the treatment of choice. Voice quality is preserved 
near normal and surgery is reserved for salvage on failure of radiotherapy. 
b. T2b lesions- these lesions are more infiltrative. The best treatment is VPL 
(Vertical Partial Laryngectomy) or supracricioid laryngectomy with CHEP 
(Crico-hyoido-epiglottopexy). Voice quality is partially preserved with 
hoarseness common after surgery. 
RADIOTHERAPY FOR EARLY STAGE GLOTTIC CARCINOMA 
                 The concept of organ preservation as emerged ever since the Radiotherapy as 
proven its role in the treatment of cancer. Mainly in the Head and neck tumors it provides 
the major effect of organ preservation. 
X-Rays were discovered by William Roentgen in 1985. The first head and neck 
cancer to be cured by Fractionated Radiotherapy was in 1928 and since then various 
modalities and combinations with chemotherapy have been tried to increase the cure rate 
in these cancers. 
                   Radiotherapy can be administered either Pre operatively, Post operatively or 
it can be definitive treatment with radiation alone in early stage tumors. 
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                   In case of postoperative Radiotherapy it should be administered after 4-6 
weeks of surgery.  Indications are advanced T stage, multiple node positivity and 
perineural or lymphovascular invasion. Post-operative chemo radiation is indicated in the 
case of positive margins and extracapsular extension (NCCN recommendation). 
                  The fractionation of radiotherapy can be of different types as follows- 
 
CONVENTIONAL FRACTIONATION: 
                   As definitive modality, a dose of 66-74 Gy is recommended to the gross 
disease and 44-64 Gy to the subclinical disease ( NCCN recommendation ), in a schedule 
of 2 Gy per fraction 5 days a week. 
ALTERED FRACTIONATION: 
Accelerated Radiotherapy: 
Decreases the overall treatment time so that the tumor cells regenerate less during the 
treatment and hence better loco regional control is achieved (36). 
Pure accelerated radiotherapy: 
There is a decrease in the overall treatment time but no change in the total dose or 
fraction size. 
Hybrid accelerated fractionation: There are three types. 
Type A: Drastic reduction in overall treatment time and a considerable decrease in the 
total dose. 
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Type B: Treatment time is decreased, total dose remains the same with an added break in 
between treatment (67.2 Gy in 42 fractions of 1.6 Gy twice daily over 6 weeks, including 
a 2-week break). 
Type C(Accelerated concomitant boost): Total dose is same; overall treatment time is 
reduced with concomitant boostregimen (72 Gy in 42 fractions over 6 weeks, with 1.8 Gy 
daily for the first 3.6 weeks and 1.8 Gy [large field] plus 1.5 Gy [boost field], 6 hours 
apart, for the last 2.4 weeks)(36). 
Hyper Fractionated Radiotherapy:  Dose of radiation is increased, dose per fraction is 
significantly reduced, the numbers of fractions are increased and overall treatment time is 
significantly unchanged (81.6 Gy in 68 fractions over 7 weeks, with 1.2 Gy given twice 
daily) 
PALLIATIVE RADIOTHERAPY: 
               In patients who presents with very advanced stage, such cases cure is not 
possible as effort to alleviate the symptoms.  In these cases, radiation is mostly given in 
hypofractionated schedules. 
For the treatment of early stage glottic carcinoma, the standard treatment has been 
to give radical radiation in standard fractionation of 1.8-2 Gy per fraction, upto 70 Gy, 
treating a small field of 4cmX 4 cm, 5cm X 5 cm, or upto a maximum of 6cm X 6 cm. 
The five-year local control rates have been reported to be 85-94% in T1 larynx (24) and 
69-80% in T2 larynx (25). These results are however, not satisfactory and there has been 
some attempt at trying to improve local control using different strategies. Such strategies 
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include higher total dose, hyperfractionated radiotherapy, concurrent chemotherapy and 
hypofractionated radiotherapy. Some reports have shown improved results with higher 
dose per fraction than the standard 2 Gy per fraction or lower (26). While the advantage 
of higher dose per fraction is attractive, issues that deal with normal tissue toxicity needs 
to be addressed, like acute mucositis, dermatitis, late laryngeal edema and cartilage 
necrosis. Higher dose per fraction treatment also require plans that give better dose 
distribution. This can be achieved by using plans that include parallel opposed wedged 
techniques. 
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REVIEW OF LITERATURE 
BIOLOGICAL BASIS OF FRACTIONATION 
From experimental data it was evident that the benefits of fractionation were due to four 
factors, which are known as, 
1. Repair 
2. Reassortment 
3. Repopulation 
4. Reoxygenation  
In general repair and repopulation will tend to make the tissue more resistant 
whereas reassortment and reoxygenation tend to make it more sensitive (27). Tumour, 
Early responding tissue and Late responding tissues are having different cell kinetics, so 
they are affected by these 4 factors in different ways.  
The Strandquist plot is the relation between the total dose and overall treatment 
time.The extra dose required to counteract tumour proliferation in a fractionated 
treatment is a sigmoidal function of time. The Ellis NSD system made the important 
contribution of separating the effects of number of fractions and overall time. 
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THE LINEAR – QUADRATIC MODEL 
The L.Q model (28) explains that the radiation cell kill has 2 components. The 
initial linear component (D) is due to single track events and quadratic component (D²) 
is due to two track events.  
                             S=exp(-D - D²)  
S is the fraction of cells surviving a dose D.  
This model explains why there are different responses between tumor, early 
responding tissues and late responding tissues; this is due to difference in repair capacity 
or shoulder shape of underlying dose-response curve. The dose response curve of late 
responding tissue is more curved than that of tumor and early responding tissue.  
In terms of linear quadratic relationship between effect and dose, this translates 
into a larger  / ratio for early, tumor than for late effects, / ratio is the dose at which 
linear and quadratic components are equal. So, by dividing total number of doses, 
preferentially reduces the late effects. The early responding tissue and tumor tissue, 
particularly, squamous cell carcinoma in head & neck have a large / ratio. It is usual in 
radiotherapy to compare different fractionation regimens using BIOLOGICAL 
EFFECTIVE DOSE or equivalent doses (BED). Using L.Q. Model, as suggested by 
Jack Fowler at ASTRO and ESTRO Tutorials,  
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 E/  =  (nd) × (1 + d /(α/ß)  
E/  - Biologically Effective Dose   n   - Number of fractions  
            d   - Dose per fraction.  
According to the linear quadratic Model, Biological Effective Dose for a dose 
66Gy, delivered in 5.3 weeks in 6 fractions per week is 72.4Gy. The / ratio for glottic 
tissue is 9.9. 
 
RATIONALE FOR USING HYPOFRATIONATED RADIOTHERAPY 
Hypofractionation is defined as the use of doses per fraction higher than 2.0Gy. 
The total number of fractions is reduced, hence the prefix ‘hypo-’. 
 In the developmental days of radiotherapy, it was believed that fractionated 
radiotherapy was thought to be inferior to the conventional fractionation and was judged 
to be a primitive method. The importance of hypofractionated radiotherapy was 
established in the early 1950s where Lars Leksell and Borge Larasson worked together to 
create the first Gamma Knife (Elekta AB) in Stockholm. Thus, its use and popularity 
became more common, making it a technique to be exploited in the use of treating 
cancer. 
 The rationale behind using hypofractionated radiotherapy is that with increased 
dose per fraction, there is an increase in cell kill. When this method is employed, it 
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results in a shorter treatment time, which is beneficial for the patient in spending less 
days for treatment as well as to decrease the work burden on the centre providing 
treatment.  
 Another factor to take into account is tumor repopulation. This is the phenomenon 
by which treatment with any cytotoxic agent, including radiation, can trigger surviving 
cells (clonogens) in a tumor to divide faster than before. This is known as accelerated 
repopulation. During the time that the tumor is overtly shrinking and regressing, the 
surviving clonogens are dividing and increasing in number more rapidly than ever. 
Withers and colleagues surveyed the literature on radiotherapy for head and neck and 
estimated the dose to achieve local control in 50% of cases as a function of overall 
duration of fractionated treatment. The analysis suggests that clonogen repopulation in 
this human cancer accelerated at about 28 days after the initiation of radiotherapy in a 
fractionated regime. A dose increment of about 0.6 Gy per day is required to compensate 
for this repopulation. Such a dose increment is consistent with a 4-day clonogen doubling 
rate, compared with a median of about 60 days for unperturbed growth.  
The conclusion to be drawn from this is that radiotherapy, at least for head and 
neck cancer, and probably in other instances also, should be started as soon after it has 
begun as practicable. It may be better to delay the initiation of treatment than to introduce 
delays during treatment. If overall treatment time is too long, the effectiveness of later 
dose fractions is compromised, because, the surviving clonogens in the tumor have been 
triggered in to rapid repopulation. Late effects depend primarily on total dose and dose 
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per fraction; overall treatment time within the usual therapeutic range has little influence. 
Overall treatment time affects both acute effects and tumor control.  It is now well 
documented for head and neck cancer, that, local control is reduced by about 0.4 -2.5% 
for each day that overall treatment time is prolonged.  
To overcome these problems altered fractionations schedules have been studied in 
various trials. 
However, the disadvantage with hypofractionation is the increased chances of 
toxicity to late responding tissues due to the fall in the iso-effective dose for the same. 
Radiobiology explains that hypofractionation will lower the therapeutic ratio between 
tumors and late-responding normal tissues, compared with conventional fractionation, in 
the same overall time. This expectation depends on the α/β ratio for the tumor being 
considerably higher than for late-responding normal tissues; exceptions could therefore 
occur for tumors that have low α/β ratios, for example some melanomas, liposarcomas 
and potentially early-stage prostate and breast cancer. Hypofractionation is considered to 
be superior to conventional fractionation in these cases based on studies (29). 
The therapeutic gain factor for any dose per fraction is derived from the relative 
isoeffect doses for the tumor and the normal tissues. However, short intensive schedules 
compare favorably to protracted lengthy schedules in terms of tumor and late responding 
tissues. 
 The linear quadratic equation can be used to calculate the isoeffect relationships of 
radiotherapy. The simplest method to compare the iso-effectiveness of different doses per 
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fraction and different total doses is to convert the schedule into an equivalent schedule 
with 2 Gy per fraction to give the same biologic effect. 
 Another reason for the feasibility of hypofractionated radiation therapy in early 
glottic cancer is due to the fact that squamous cell carcinoma of the glottis is usually well 
differentiated and a slowly growing lesion (30). 
In a study done by Krzysztof Skladowski et al., the dose along with the overall 
treatment time was established. They also took into account the pretreatment hemoglobin 
level of the patient. In this study, 235 patients with T1N0M0 glottic cancer were recruited 
and treated by radiation therapy alone given in a conventional schedule with 5 fractions 
each week. The individual total dose, dose per fraction, and overall treatment time (OTT) 
ranged from 51–70 Gy, 1.5–3.0 Gy, and 24–79 days, respectively. The median follow-up 
was 48 months. Patient data—total dose, dose per fraction, Overall Treatment Time and 
hemoglobin level measured before the radiation treatment—were fitted by the mixed 
LQ/log-logistic model. They concluded that the dose–response curve for 235 patients 
with T1 glottic cancer was well defined and steep, and showed significant decrease in 
tumor control probability (TCP) when total doses were below 61 Gy. The 10-day 
prolongation of OTT, from 45 to 55 days, decreased the TCP by 13%. The dose of 0.35 
Gy/day, compensated repopulation during the 1 day of prolongation, which indicates a 
potential doubling time (Tpot) for glottic T1 tumor clonogens of 5.5 days. The drop 
of Hb level of 1 g/dl (from 13.8 g/dl to 12.8 g/dl) gave a 6% decrease of TCP, provided 
that OTT was 45 days. Therefore, dose per fraction, above 2Gy and overall treatment 
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time to around 6 weeks proves to be a schedule where acceptable tumor control is 
achieved. 
In another study where growth rate of laryngeal cancer was studied, there was a 
variable range of the rate of growth. The rate of tumor growth seemed to be an important 
factor for Disease Free Survival and Overall Survival. This tumor growth rate is 
independent of age, differentiation and tumor volume associated with DFS, but N-stage 
seems to be a more important risk factor (31). There are sparse lymphatics in the 
laryngeal glottis, hence, the major risk factor can be taken into less consideration when 
analyzing the factors that affect the growth rate of the tumor, which in turn, affect the 
DFS and OS. This study showed that tumors that grow rapidly had a worse outcome in 
the form of decreased DFS.  
Tumor location Number N% Slow Growth 
Rate 
Fast Growth 
Rate 
Glottic 64 48.9 49 15 
Supraglottic 66 50.4 34 32 
Subglottic 1 0.7 0 1 
T 1 2 1.6 2 0 
T 2a 37 28.2 27 10 
T 2b 38 29 26 12 
 
Table showing the incidence of fast and slow growing tumors in laryngeal carcinoma 
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As not many studies have been done to correlate the tumor growth rate and its 
association to DFS or OS, we take this study into account for the number of patients and 
the number of  tumors which show either fast or slow growth rate. The statistics in this 
study show that most of the early staged laryngeal tumors show slow growth pattern. In a 
subset analysis of the glottis, 49out of 64 glottic cancer patients showed slow growth rate 
in the tumor, while the other 14 showed faster growth rate. Hence, we can conclude that 
not only for most early laryngeal cancer but for early stage glottis cancer, most of the 
tumors are slow growing. The method of the study was done as follows. 
In this study they delineated the tumor according to abnormal contrast 
enhancement, soft tissue thickening, presence of a mass lesion, infiltration of fatty tissue, 
or a combination of these. Delineation on both scans was performed using 3-D 
delineation software (in-house developed). This software package (VolumeTool) includes 
image quantification tools such as volumetry and 3D visualization. The delineation 
package is based on a combined Java/C+ library and includes a (in-house developed) 
DICOM server for storing image data-sets as well as delineated structures sets. Tumor 
growth rate was then calculated by taking the interval (in days) between the two CT scans 
and recording the findings. Tumor growth was based on the volume difference between 
the diagnostic and planning CT-scans. Exponential growth was assumed (32). 
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Tumor Growth Rate (TGR) = ln(Vplan- Vdiagn) / T 
Vdiagn= tumor volume on dCT;  Vplan 
    =tumor volume on pCT; T 
     = days between dCT and pCT 
(Where dCT is diagnostic CT scan and pCT is planning CT scan) 
 
The end point was Disease Free Survival. The mean time between the dCT- and 
pCT scans was 25.7 days (SD 11.6). The mean tumor growth rate was _0.3 ln(cc/day) 
and, therefore, this was used as cut-off point . In a subset analysis taking only glottic 
cancers into account, 49 out of the 64 patients showed a slow growth rate and the rest 
showed a fast tumor growth rate. This study found a significant association with DFS 
(HR 2.4; 95% Confidence Interval (CI) 1.3–4.4) and OS (HR 1.9; CI 1.2–3.2).  
Fast growing tumors (n = 48) had a 5 year DFS and OS of 56% and 40% 
respectively compared with 78% and 65% in slow growing tumors (n = 83). 
 
Thus, slow growing tumors can be taken as a more common phenomenon in a 
population of early glottic cancer. From the general idea we have of slow growing 
tumors, it can be safe to say that there are multiple studies showing the efficacy of 
hypofractionated radiation therapy over standard fractionation.  Therefore, the patient 
population in this study has been assumed to be amenable to hypofractionated radiation 
therapy as all, except one patient are of squamous cell carcinoma and all patients are 
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early stage, without lymph node metastases, which would have otherwise influenced the 
outcome independent of tumor growth (33). 
The glottis is a structure devoid of lymphatics. Lymph node metastases become 
apparent only when there is extension into the supraglottis or subglottis. 
The incidence of lymph nodes metastases is given as follows: 
STAGE LYMPH NODE METASTASIS 
T1 ≤ 2% 
T2 5% 
T3 20%-30% 
T4 40% 
 
In early stage glottic carcinoma, i.e, T1 & T2 tumors, there is very minimal lymph 
node spread and therefore the prophylactic or therapeutic treatment of the neck or its 
echelon lymph node stations are not required unless there is obvious involvement of the 
lymph nodes. Hence, the standard of treatment in early stage glottic cancer consists of a 
small field, shaped like a box, with a margin wide enough to cover the entire glottis, 
keeping in mind the change in position of the structure in case of swallowing and to make 
up for set up errors. This small treatment field allows us to treat the tumor in an increased 
dose per fraction, taking into account toxicity to normal tissues.  
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Thus, taking all these factors into account, hypofractionation seems like not only a 
feasible approach, but also advantageous in terms of tumor biology and patient factors. 
 
RATIONALE OF USING BEAM MODIFICATION TECHNIQUES 
TYPES OF BEAM MODIFICATION 
– Shielding: To eliminate radiation dose to some special parts of the zone at 
which the beam is directed. 
– Compensation: To allow normal dose distribution data to be applied to the 
treated zone, when the beam enters a or obliquely through the body or 
where different types of tissues are present. 
– Wedge filtration: Where a special tilt in isodose curves is obtained. 
– Flattening: Where the spatial distribution of the natural beam is altered by 
reducing the central exposure rate relative to the peripheral. 
TYPES OF BEAM MODIFICATION DEVICES 
• Field blocking and shaping devices: 
– Shielding blocks. 
– Custom blocks.  
– Asymmetrical jaws. 
– Multileaf collimators. 
• Compensators. 
• Beam spoilers 
• Wedge filters. 
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• Beam flattening filters. 
• Bolus 
• Breast cone 
• Penumbra trimmers. 
• Electron beam modification 
In this study, wedge filters and bolus were used for every patient during treatment. 
 
WEDGE FILTERS 
This is the most commonly used beam modifying device. It is mounted into the 
tray and placed 15 cm away from the skin surface. Wedges come  in 4 angles 
15,30,45 and 90 degrees. Wedge filters offer dose homogeneity for irregular 
surfaces(34). 
As the angle increases- 
     -Attenuation produced by the thicker end (heel)increases . 
   - Dose transmission from thinner end(toe) thus tilting of isodose curve increases. 
Wedge Field Techniques (hinge angle and wedge angle)  
 
 
 
BOLUS 
2
90
angle  wedge 





angle hinge 
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A tissue equivalent material used to reduce the depth of the maximum dose (Dmax). 
It is better called a “build-up bolus”. A bolus can be used in place of a 
compensator for kilovoltage radiation to even out the skin surface contours. In 
megavoltage radiation bolus is primarily used to bring up the buildup zone near 
the skin in treating superficial lesions. The thickness of the bolus used varies 
according to the energy of the radiation. 
In megavoltage radiation: 
– Co60 : 2 - 3 mm 
– 6 MV : 7- 8 mm 
– 10 MV : 12 - 14 mm 
– 25 MV: 18 - 20 mm 
Properties of an ideal bolus are that it should have the same electron density and 
atomic number as the tissue being irradiated, it should be pliable to conform to 
surface with a usual specific gravity of 1.02 -1.03. 
• Commonly used materials are: 
– Cotton soaked with water. 
– Paraffin wax. 
• Other materials that have been used: 
– Mix- D (wax, polyethylene, mag oxide) 
– Temex rubber (rubber) 
– Lincolnshire bolus (sugar and mag carbonate in form of spheres) 
– Spiers Bolus (rice flour and soda bicarb) 
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• Commercial materials: 
– Superflab: Thick and doesn't undergo elastic deformation. Made of 
synthetic oil gel. 
– Superstuff: Add water to powder to get a pliable gelatin like material. 
Bolx Sheets: Gel enclosed in plastic sheet. 
 
 
 SUPPORTING STUDIES 
 
KROG-0201- the aim of this trial was to prospectively investigate the effect of 
fraction size of radiotherapy and its outcome in early glottic carcinoma. This trial 
compared two arms- one that of conventional fractionation 66 Gy in 33 fractions for T1 
disease, 70 Gy in 35 fractions for T2 disease and a hypofractionation arm 63 Gy in 28 
fractions for T1 disease and 67.5 Gy in 30 fractions for T2 disease. All patients were 
followed up for 67 months and the primary objective was local progression free survival. 
The 5-year local progression free survival for the conventional arm was 77.8% and 
88.5% for the hypofractionated arm(35). There was no difference in toxicity in both 
the arms. This study established the fact that hypofractionation is not inferior to 
conventional radiation in terms of local control and toxicity. This method of treatment 
proved that hypofractionated radiotherapy can be given for early T1 and T2 lesions in 
carcinoma of glottis with advantages of potential better local control and shortened 
treatment time. 
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  A Japanese study by Onimaru et al was done in 200 patients with T1-T2 glottic 
cancers to investigate the importance of the overall treatment time by giving 
hypofractionated radiation therapy 2.5 Gy per fraction for a total dose of 65 Gy, four 
fractions a week. It was found that patients who completed the treatment within 46 days 
had a significantly better local control (91.9±2%) than those (36) who completed 
treatment in 47 or more days ( 82.6±6%). 
 Ermis et al conducted a retrospective analysis with hypofractionated radiotherapy 
with 55Gy in 20fractions at 2.75Gy per fraction in 132 patients. Five year local control 
and overall control rates were 85.6 % and 97.3 % respectively, with T1a  having  
91.8 %  and 100 %, T1b - 81.6 and 93.8 %, and T2 - 80.9 % and 95.8 % (37).Only 
one patient needed tracheostomy due to a non-functioning larynx while on long term 
follow up. This study concluded that hypofractionated radiation therapy for early stage 
glottic cancer shows high rates of local control with acceptable toxicity. 
 Another study from Japan done by Karasawa et al evaluated the effect of 
hypofractionated radiation therapy in 69 patients of early glottic cancer with  
2.25 Gy per fraction upto a total dose of 63 Gy treated within a median time of 41 days. 
One case of T2 glottic cancer could not reach complete response , but all other cases 
achieved complete response. The 5-year LC rates in larynx T1 and larynx T2 were  
97.6%,  and 70.1%, respectively (38). No acute adverse effects more than Grade 2 
toxicity (CTCAE 3.0) were seen. They concluded that this treatment was safe and 
valuable in treating early glottic cancer, with T1 showing a better outcome compared to 
historical data. For T2, local control did not show any improvement compared to 
 43 | P a g e  
 
historical data and treatment strategy that involves dose escalation is needed for these 
tumors. 
 Khan et al conducted a retrospective analysis to evaluate the patient, tumor and 
treatment characteristics in patients with early glottic carcinoma in 141 patients. Therapy 
consisted of 2.2 Gy per fraction for 25 fractions upto a total dose of 55 Gy within 5 
weeks with the help of 6 MV linear accelerator. The 5-year  local control rates were as 
follows:T1a, 94%; T1b, 83%; T2a , 87%; T2b, 65% (39).The 10-year  local control 
rates were as follows: T1a, 89%;T1b, 83%; T2a, 87%; T2b, 56%.  This study highlighted 
the improvement in voice quality post radiation therapy in those patients who 
initially had poor voice quality. 73% out of the 92% of patients experienced an 
improvement, and none of the patients suffered severe or fatal complications. They 
concluded that definitive radiotherapy offered excellent local control in T1-T2a, N0 
glottic carcinoma along with good voice preservation and minimal long term toxicity. 
T2b tumors had an inferior response and alternative strategies may be considered. 
 Mendenhall et al described a local control of 94%, 93%, 80%, 72% for T1a, T1b, 
T2a and T2b respectively for patients treated with 2-2.25 Gy per fraction,  one fraction 
daily.  Out of the 519 patients received radiotherapy at the University of Florida 
(Gainesville, FL) for T1N0–T2N0 glottic carcinoma, six patients developed severe 
complications, including severe mucositis necessitating hospitalization and a treatment 
break ,  total laryngectomy for a suspected local tumor recurrence with a pathologically 
negative specimen. laryngeal edema, and a pharyngocutaneous fistula after a salvage total 
laryngectomy (40). Five of these patients had T2N0 disease. None of these patients died.  
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 Laskar et al conducted a retrospective analysis to evaluate the effect of dose and 
fractionation with respect to tumor characteristics , toxicity and outcome in patients with 
T1N0 glottic cancer. The records of 652 patients were analyzed. The four 
hypofractionated schedules were 50 Gy in 15 fractions (3.3 Gy per fraction), 55 Gy in 16 
fractions (3.43 Gy per fraction), 60 Gy in 24 fractions (2.5 Gy per fraction) or 62.5 Gy in 
25 fractions (2.5 Gy per fraction). The patients were categorized into two groups of < 3 
Gy or > 3 Gy. All patients were treated with 6MV photons in linear accelerator. Local 
control in 10 years was 84% and overall survival was 86.1% (41) for T1 glottic 
carcinoma. Persistent laryngeal edema was seen in 123 patients. This study concluded 
that hypofractionated radiation therapy offers acceptable local control rates and late 
toxicity as long field size was restricted to 36 cm2. 
 Short et al conducted yet another study to analyze the effect of dose and 
fractionation compared to standard fractionation (SFX) in T1, T2 N0 tumors in glottic 
cancer. This New Zealand study employed Accelerated Hypofractionated Radiation 
Therapy ( AHFX), with 145 patients receiving this treatment. The treatment consisted of 
60-66 Gy in 30-33 fractions  (SFX) with 60 Co and 6 MV beams. AHFX consisted of 
52.5-55 Gy in 20 fractions over 4 weeks using 60 Co and 6 MV beams. The 5-year overall 
survival was 78%. The 5-year loco-regional control for T1was higher in AHFX (42) 
compared to SFX. Locoregional control in T2 was similar in both fractionation schedules. 
None of the patients had grade 4 or 5 late reactions. These results showed that AHFX is 
comparable to standard fractionation regimen with equivalent local control and toxicity. 
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 Spector et al evaluated the therapeutic outcome of dose on the voice quality and 
preservation in patients treated with low dose, high dose radiation therapy and surgery. 
This retrospective study analyzed 625 patients who were divided into four groups- low 
dose radiation- 55-65 Gy, in 1.5-1.8 Gy per fraction, high dose radiation with 65-70 Gy 
in 2-2.25 Gy per fraction daily. 404 patients underwent conservation surgery and 61 
underwent endoscopic resection. The overall local control was 89% and the overall 
unaided laryngeal voice preservation was 90%. Actuarial survival was significantly 
decreased in the low dose group was compared to the other groups. This study concluded 
that the four treatments used provide similar rates of survival and ultimate local control 
(43). The low dose arm was associated with lower actuarial overall survival and unaided 
voice preservation. Hence, the survival, local control and voice preservation rates were 
comparable in all groups except for low dose radiation group which showed a lower 
overall survival and unaided voice preservation. 
 Quynh-Thu X. Le et al performed a prospective study in the University of 
California to assess the significance of fraction size, total dose and overall treatment time 
in the control of T1-T2, N0 glottic carcinoma. A total of 398 patients were recruited and 
treatment was delivered in 5 days per week. Minimum tumor dose ranged from 46.6- 
77.6 Gy , with a median dose of 63 Gy. The fraction size was <1.8  Gy in 146 patients, 
1.8-1.99 Gy in 128, 2-2.24 Gy in 62 and 2.25 Gy in 62 patients. All patients were treated 
within a median of 50 days. 5 year control was 85% for T1 and 70% T2 glottic 
carcinomas (44).  For the T1 lesions, there was no apparent relationship between the 
fraction size, overall time and total dose with respect to local control on multivariate 
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analysis. For T2 lesions, local control rate was 100% for the patients treated with 43 days 
overall time, 2.25 Gy per fraction. Local control was 44% for those treated with fractions 
size <1.8 Gy, 78% for those treated with a total >65 Gy. This study concluded that factors 
like total dose and overall treatment time were significant factors when considering the 
treatment and local control of T2 but not T1 glottic carcinomas. Anterior commisure 
involvement was also associated with lower local control rates for T1 but not T2 lesions.  
 
 Gowda et al. conducted a study in T1 glottic tumors with invasive squamous cell 
carcinoma. All patients were treated with definitive radiotherapy with a  total tumor dose 
of 50-52.5 Gy in 16 fractions over 21 days. The fraction size ranged from 3.12 to 3.28 
Gy. This study achieved  5-year local control rates of 93%; there were 14 
recurrences of which seven were successfully salvaged by surgery, giving an 
ultimate local control of 96% (45). The 5-year overall survival was 80% and cause 
specific survival was 97% at 5 years.  
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 48 | P a g e  
 
 
 
 
AIM AND OBJECTIVES 
 
 
The aim of this study was to evaluate the influence of dose per fraction in early 
glottic carcinoma. 
Primary objective: To assess the immediate loco regional response rates of 
hypofractionated radiation in early glottic carcinoma. 
Secondary objective: To assess the early toxicity of hypofractionated radiation in 
early glottic carcinoma. 
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MATERIALS AND METHODS 
 
STUDY DESIGN: this was a single arm prospective study with a Phase II design. 
STUDY DURATION: October 2016– August 2017. 
STUDY CENTRE: 
This study was conducted in Department of Radiotherapy, Barnard Institute of 
Radiology & Oncology, Madras Medical College, Chennai. 
 
SAMPLE SIZE:  
30 consecutive patients with histo-pathologically proven squamous cell carcinoma 
of who fulfilled early stage glottic carcinoma who fit into the inclusion criteria were 
recruited in the study from the outpatient department.  
The intent of treatment was to be radical, aiming for cure, considering their 
disease stage, co- morbidities and performance status 
ETHICAL COMMITTEE APPROVAL: Approval from the institute ethical committee 
was obtained on 4/10/2016. 
INFORMED PATIENT CONSENT:  
All patients enrolled in the study were informed about the merits and demerits of 
participating in this study and signed an informed consent form in their regional 
language, which is Tamil. 
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INCLUSION CRITERIA: 
 Biopsy proven newly diagnosed squamous cell carcinoma of the glottis. 
 Stage T1 and T2 , N0M0  disease  
 Age 20 - 70 years 
 ECOG 0-1 performance status  
 No major life threatening comorbidities 
 
 
EXCLUSION CRITERIA: 
 Patient who did not consent for radiation at any point of time during treatment.  
 Patients with history of any malignancy previously and received treatment for the 
same. 
 Recurrent tumors. 
 Previous history of radiation or surgery to the area planned for treatment. 
 Patients with collagen vascular disease 
 Pregnant females 
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PRE TREATMENT WORK UP: 
1. Detailed history elucidation. 
2. Complete physical examination by inspection, palpation. 
3. Upper aerodigestive tract evaluation by direct and indirect laryngoscopy, anterior and 
posterior rhinoscopy and endoscopy if indicated to know the extent of disease and rule 
out a second primary. 
4. Biopsy from the primary tumor  
5. Blood grouping and typing. 
6. Complete blood count. 
7. Renal function test. 
8. Liver function test. 
9. CT scan of the head and neck, plain and contrast, before initiating treatment and also 
after treatment for response assessment. 
10. Chest X ray postero-anterior view.  
11. Cardiac evaluation and fitness.  
12. Tumor stage, performance status and weight were recorded. 
Staging was done based on American Joint Committee staging manual 7th edition (for 
head and neck cancers). 
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PATIENT PREPARATION DURING TREATMENT: 
All patients enrolled in the study were distributed pamphlets describing in brief the 
do’s and don’ts while on treatment and later.  
Quitting alcohol and tobacco  
The harmful effects of tobacco, both in smoking and nonsmoking form, and 
alcohol were explained to the patient and their addictions as inferior outcome after 
treatment. Also has increased risk of second malignancy due to field cancerization effect. 
Mucositis 
The major side effect of chemoradiotherapy/radiotherapy is mucositis, a condition 
where patient perceives pain due to inflammation and ulceration of the mucosa. It occurs 
mainly due to disruption of normal mucosal barrier by radiotherapy causes production of 
Reactive Oxygen Species resulting in increased production proinflammatory cytokines 
(IL-1β, IL-6) which causes tissue injury and apoptosis of cells in the mucosa. 
Retrospective review of over 200 head and neck cancer patients treated with 
radiotherapy at MD Anderson cancer centre, 66% of the patients had either grade 3 or 4 
mucositis. According to various studies patients with oral cavity, nasopharynx, 
oropharynx cancer treated with concurrent chemotherapy or altered fractionation 
radiotherapy, had a higher rate of mucositis producing intense pain, weight loss, and 
treatment breaks which compromises loco regional control.  
 Studies show that daily dose, cumulative dose and volume of irradiated 
tissue determine the severity of mucositis. This pain produced by mucositis can lead to 
nutrition compromise thereby lack of proper hydration and oral hygiene. The 
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desquamated epithelium, fibrin, and polymorphonuclear leukocytes in a moist 
background provide a favorable environment for opportunistic infections such as 
candidiasis.  
 
 Radiation to a small field in case of early glottic cancer can cause mucositis of the 
esophageal and pharyngeal mucous membranes. According to studies, when radiation 
therapy is the only treatment used, esophagitis usually has its onset at about 20-30 Gy, or 
two to three weeks after treatment. This condition usually begins to subside 10 days to 2 
weeks after radiation therapy is completed. This is best accomplished if the patient’s 
nutritional status is maintained at an optimal level. Immunocompromised patients can 
have persistent symptoms and the patient needs to be assessed for candidiasis. 
 
NUTRITIONAL CARE: 
Most of the Head and neck cancer patients suffer from dysphagia and odynophagia 
either because of the tumor or due to treatment related effects like mucositis. This can 
affect the quality of life results in decreased food intake and they become nutritionally 
deprived resulting in weight loss. 
All patients enrolled in this study were given dietary advice and encouraged to 
take easily available, nutritionally rich local foods, dairy products and fresh fruits and 
juices (avoid citrus fruits, acidic and spicy foods). Everyone was encouraged to take 
supplemental calories before treatment consisting of  two raw eggs and milk daily. 
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Homemade preparation of health mix with milk which is rich in protein is given  
to regenerate tissue protein. Pureed or soft meals preparation at room temperature is also 
a preparation that has found to be well accepted. All patients were monitored for weight 
loss every week and special meals were designed for individual patients. 
Mostly during third or fourth week of radiation patients develop severe mucositis 
and need supplementary nutrition. Parenteral nutrition was also given if needed.Those 
patients who developed grade 3 or 4 dysphagia were intubated with a naso-gastric tube so 
that nutrition was not compromised.  
Before initiation of treatment, it was made sure that all patients had normal blood, 
renal and liver function tests and everyone as given written consent for the treatment. 
TREATMENT PROTOCOL: 
30 cases of early staged glottic cancer patients were selected consecutively from 
the outpatient department, who then underwent the pre treatment work up as mentioned 
before. 
RADIATION THERAPY:  
All patients were treated with a accelerated dose schedule of 2.25 Gy per fraction 
with a Theratron Phoenix Tele Cobalt-60 machine, using wedges of either 30° or 60° to 
achieve dose homogeneity along with bolus on the surface of the patient to be treated to 
achieve adequate dose to the anterior commisure, especially if it is involved. 
 
Patient Position:  
Patients were made to lie in the supine position with neck slightly extended.  
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Patient Immobilization:  
Strict immobilization was practiced while irradiating the patient.  
Radiation Portals:  
Patients were treated with opposing lateral radiation portals 
Verification:  
X-ray simulation was done with the patient in treatment position to verify the 
treatment field.  
Radiation Dose:  
Patients were treated with a dose of 2.25 Gy per fraction, with 6 fractions per 
week, up to a total dose of 63Gy. Aim was to complete radiation within 5.6 weeks. 
Appropriate shielding was done to limit the spinal cord dose to 40 Gy as per the 
institutional policy.  
ASSESSMENT DURING RADIATION:  
Toxicity Assessment:  
Patients were reviewed every day before radiation for any acute toxic reactions and 
infections. Reactions like skin desquamation, mucositis, laryngitis, dysphagia etc. were 
recorded and graded based on RTOG acute radiation morbidity criteria. If a patient 
developed grade 3 or higher reactions radiation was suspended. Careful attention was 
given for maintenance of hydration, adequate dietary intake and good oral hygiene.  
 Hematological and renal parameters were assessed on a weekly basis. Hemoglobin 
less than 10 mg/dl was corrected by packed red cell transfusion. WBC and platelet counts 
were kept under regular monitoring.  
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RESPONSE EVALUATION:  
All patients were reassessed by clinical examination and with a CT Neck, 4 -6 
weeks after completion of radiation.  
Response to treatment was described based on the Response Evaluation Criteria in Solid 
Tumors (RECIST 1.1 version) Criteria. 
 COMPLETE RESPONSE: Disappearance of all target lesions; malignant nodes 
<10 mm.  
 PARTIAL RESPONSE: At least 30% reduction in the sum of the longest 
diameter of target lesions, taking as reference the baseline study; confirmed at 4 
weeks.  
 STABLE DISEASE: Neither partial response nor progressive disease criteria are 
met, in a minimum time set by the protocol.  
 PROGRESSIVE DISEASE: At least 20% increase in the sum of the diameter, 
with a minimum absolute increase of 5 mm, taking as reference the smallest sum 
in the study or appearance of new lesions.  
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FOLLOW UP: 
 
 Patients after completion of concurrent radiation were discharged from the 
hospital. Response evaluation was done based on RECIST criteria after 4-6 weeks.  
 Chest imaging was done when indicated clinically. Continued smoking cessation, 
counseling to the patient and their attendee, rehabilitation, speech and swallowing 
therapy.  
STATISTICAL ANALYSIS:  
The patient factors, tumor factors, response to treatment, and toxicities were 
thoroughly analyzed. The results are expressed in percentage. Since this  study is single 
armed one and also the sample size was only 30, the levels of significance cannot be 
commented on. 
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CASE ANALYSIS 
AND 
RESULTS 
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RESULTS AND ANALYSIS 
The total 30 patients recruited completed their entire treatment protocol and all of 
them were available for analysis of results.  
PATIENT CHARACTERISTICS:  
AGE DISTRIBUTION: 
43% of the patients belonged to the age group 51- 60yrs, followed by 41 -50yrs. 
The mean age of presentation was 55.5yrs. The youngest patient age was 35yrs 
and the oldest was 64yrs. 
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Figure No: 1, AGE DISTRIBUTION 
 
 
 
AGE GROUP  
 
NUMBER  
 
PERCENTAGE  
 
31- 40yrs  
 
6  
 
20%  
 
41 -50yrs  
 
9  
 
30%  
 
51-60yrs  
 
13  
 
43%  
 
61- 70 yrs 
 
4 
 
7% 
 
Table No: 1, AGE DISTRIBUTION 
AGE DISTRIBUTION
31-40 years
41-50 years
51-60 years
61-70 years
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Table  no: 2, GENDER DISTRIBUTION OF THE STUDY POPULATION 
 
 
SEX  NO. OF PATIENTS  PERCENTAGE  
MALE  24  80%  
FEMALE  6  20%  
 
 
Figure no: 2, Gender distribution of the study population   
 
 
 
 
MALE ,  24 ,  80 % 
FEMALE ,  6 ,  20 % 
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PERFORMANCE STATUS:  
All patients in this study had a general performance status of  
ECOG (Eastern Cooperative Oncology Group)grade 0 or 1.(figure no:3)  
 
Table no:3, ECOG performance status  
ECOG  NO.OF PATIENTS  PERCENTAGE  
ECOG 0  18  60%  
ECOG 1  12  40%  
 
 
Figure no:3, ECOG performance status  
 
 
 
 
ECOG 0 
60 % 
ECOG 1 
40 % 
ECOG 
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HABITS:  
 
 In the natural history of head and neck cancer, habits /addictions of the patients 
to tobacco, alcohol plays a major role. In this study, as expected, majority of the 
patients had habit of both tobacco (smoking and smokeless) and alcohol   
Table no: 4, Habits / addictions in the study population.  
 
HABITS  NO.OF PATIENTS  PERCENTAGE  
TOBACCO(SMOKING)  19  63%  
TOBACCO(SMOKELESS)  11  36%  
ALCOHOL  16  53%  
NONE  4  13%  
 
 
SYMPTOMS AND SIGNS:  
The most common symptom of presentation among the patients in this study was a 
change in voice or hoarseness of voice. 
Some complained of sore throat, but none complained of pain, or difficulty in 
swallowing or any palpable neck nodes. 
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PRESENTING 
SYMPTOMS/SIGNS  
 
NUMBER  
 
PERCENTAGE  
VOICE CHANGE 26 87%  
SORE THROAT 4 13%  
PAIN 5  16%  
DYSPHAGIA 2 7%  
NECK SWELLING 0 0%  
Table No:5, Presenting Signs and Symptoms 
 
 
Figure No:5, Presenting Signs and Symptoms 
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PRIMARY SITE: 
Table no:6, Primary site  
PRIMARY SITE  NUMBER  PERCENTAGE  
RIGHT VOCAL CORD 17 56%  
LEFT VOCAL CORD 14 46%  
ANTERIOR COMMISURE 
INVOLVEMENT 
13           43%  
SUPRAGLOTTIS/SUBGLOTTIS 
EXTENSION 
3           10% 
 
 
 
Figure No:6, Site of Involvement 
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In the subset analysis, the involvement of the right vocal cord was only slightly 
more common than the left vocal cord and the incidence of the anterior commisure was 
43%, i.e, in 13 patients. There was extension to supraglottis or subglottis in 3 patients. 
TUMOR STAGE: 
This study included only early stage glottic cancer, i.e, T1 and T2 with no nodal 
involvement, N0. Thirteen patients had T1N0M0 and 12 had T2N0M0 disease. Out of the 
18 patients who were staged as T1, 8 had T1a and 10 patients had T1b disease. 
     TUMOR STAGE     No. OF PATIENTS       % OF PATIENTS 
               T1a                 8                26.6% 
               T1b                10                          33.33% 
               T2                12                40% 
Table No:7, Tumor Stage 
 
 68 | P a g e  
 
 
Figure No:7, Tumor Stage 
STAGE GROUPING OF THE STUDY SAMPLE:  
  The staging grouping was done according to AJCC 7th edition. Patients were 
staged either stage I or stage II. None of the patients had nodal disease. 
STAGE GROUPING  NUMBER  PERCENTAGE  
STAGE I 18 60%  
STAGE II  12 40%  
Table No:8, Stage Grouping 
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HISTOLOGICAL DIFFERENTIATION:  
Most of the patients in the study belonged to moderately differentiated histology followed 
by poorly differentiated.  
Table No:9, Histological Differentiation 
HISTOLOGICAL 
DIFFERENTIATION  
NUMBER  PERCENTAGE  
WELL 
DIFFERENTIATION  
7  23.33%  
MODERATELY 
DIFFERENTIATED  
17  56.66%  
POORLY 
DIFFERENTIATED  
6  20%  
  
Figure No:9, Histological Differentiation 
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TREATMENT RESULTS: 
All 30 patients completed the treatment protocol and were assessed at the end of 
4-6 weeks. The evaluation was done clinically, which included ENT (Ear, Nose, 
Throat) examination with indirect laryngoscopy and direct laryngoscopy, and CT 
imaging (plain and contrast). The RECIST 1.1 criteria were used to classify the 
response type into a complete response, partial response, static or progressive 
disease. 
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RESPONSE RESULTS: 
 
Figure no:10, Response results  
RESPONSE  NUMBER  PERCENTAGE  
COMPLETE  
RESPONSE  
26 87%  
PARTIAL 
PRESPONSE  
4              13%  
STATIC RESPONSE  0  0  
PROGRESSION  0  0  
Table no:10, Response results  
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SUBSET ANALYSIS:  
All the patient characteristics were analyzed for response at the end of the 
treatment. The results are stated in percentage. Due to the single arm analysis and 
small sample size of 30 patients, the study tests of significance cannot be relied on.  
 
TUMOR STAGE Vs RESPONSE:  
 Out of the 18 T1 lesions, 17 patients had complete response whereas out of the 12 
T2 patients  9 had complete response.  
Figure no: 11,Tumor Stage Response 
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Table no:11, Tumor Stage Response   
 
TUMOR 
STAGE  
COMPLETE  
RESPONSE  
PARTIAL 
RESPONSE  
T1  17 (56.66%) 1(3.3%) 
T2  9 (30%) 3 (10%) 
 
 
HISTOLOGICAL DIFFERENTIATION Vs RESPONSE:  
 As already mentioned maximum numbers of the patients in our study were 
moderately differentiated, which accounted for 17 patients; in which 16 patients 
had complete response and 1 had partial response. Among the poorly 
differentiated cancer, 5 had complete response and 1 had partial response. Out of 7 
well differentiated tumors only 5 had complete, this is lower than patients with 
moderately differentiated tumors but almost equal to the poorly differentiated 
category.  
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Figure no:12, Histological Differentiation Vs. Response 
 
Table no: 12, Histological differentiation Vs. response 
 
HISTOLOGIC 
DIFFERENTIATION  
COMPLETE 
RESPONSE  
PARTIAL 
RESPONSE  
WELL DIFFERENTIATED  5 (16.6%)  2 (6.66 %)  
MODERATELY DIFFERENTIATED  16 (53.3%)      1(3.33 %)  
POORLY DIFFERENTIATED  5 (16.6%)  1 (3.33%) 
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These were the patients who presented with Squamous cell Carcinoma histology. 
One patient presented with Sarcomatoid histology of well differentiated category 
who showed partial response to treatment. 
PERFORMANCE STATUS Vs RESPONSE:  
The ECOG performance status among the study patients did not show much 
difference in the response rates, as the study patients are in the ECOG 0 OR 1. 
Table no: 13, ECOG Vs Response 
ECOG  COMPLETE  
RESPONSE  
PARTIAL RESPONSE  
0  14 (46.6%)  4 (13.33%)  
1  10 (33.3%)  1 (3.33%)  
 
 
AGE:  
In this study people aged less than 50yrs were 15 patients out of them 12(80%) 
had complete response. In case of above 50yrs there were  
15 patients, in which only 66% had complete response.   
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Table no: 14, Age Vs Response  
AGE GROUP  COMPLETE RESPONSE  
PARTIAL RESPONSE  
31-40Yrs  3(10%)  3(10%)  
41-50Yrs  5(16.66%)  1(3.33%)  
51-60Yrs  13(43.33%)  1(3.33%)  
61-70Yrs  3(10%)  1(3.33%) 
 
 
TREATMENT RELATED ACUTE TOXICITIES:  
ACUTE LOCAL TOXICITY:  
`             Acute local toxicity is done by RTOG Acute morbidity scoring  
criteria.(Table 15, figure no:15)  
 
SKIN REACTION:  
 
In this study 77% of the patients had Grade 1 skin reactions in the form of dry 
desquamation, decreased sweating. Another 23% had patchy moist desquamation 
whereas none of the patients had Grade 3 or 4 reactions. For those patients with grade 2 
reactions, i.e, patchy moist desquamation, hydrogel dressing was given if needed. 
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Instructions were given to maintain clean and dry skin over the irradiated area. None of 
the patients had treatment breaks due to these toxicities. 
 
MUCOSITIS:  
 Nearly 40% of the study population developed grade 2 reactions in the form of 
dysphagia and pharyngitis. Most of their diet consisted of bland, puréed food and liquids. 
None required nasogastric tube feeding or intravenous fluid with hospital stay. 
Supportive measures with analgesics, strict oral hygiene, mouth-wash with alcohol free 
antibacterial solution was adviced if needed. Also T. Dexamethasone 8mg  PO bid was 
given for 4-5 days.  
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Figure No:15, Acute Toxicities 
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Table No:15, Acute Toxicities 
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OTHER TOXICITIES: 
One patient had grade 1 laryngeal edema, which did not require hospitalization or 
tracheostomy. None of the patients had grade 3 or 4 toxicities. None of the patients had 
cartilage necrosis. None of the patients had systemic or hematological toxicity. 
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DISCUSSION 
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DISCUSSION 
The head and neck cancer census incidence is increasing in the present decade. 
Mainly in India, due to the habit and addiction towards tobacco in smoked form like 
cigarettes or beedi also in smokeless forms like pan, kurkha etc plays a major causative 
effect. As the youngster’s exposure to these agents increase, there is rise in cancer 
incidence, mainly head and neck cancer. 
As the head and neck cancer affects the quality of life in patients due to 
disfigurement, dysphagia, hoarseness of voice etc. Patients also in our country present in 
advanced stage due to lack of awareness, illiteracy, poor socioeconomic status. This gives 
them very limited treatment options. 
Cases of early glottic carcinoma commonly experience a change in voice, maybe 
associated with hoarseness and/ or sore throat. The priority of the treatment should be to 
achieve good local control and preserve the function and structure of the vocal cords and 
laryngeal structures as it is in its early. There are various options to achieve good local 
control , which include laser excision, endoscopic submucosal resection, partial laryngo-
pharyngectomy, and total laryngo-pharyngectomy. Superior organ preservation with 
better voice quality has been reported in use of radiation therapy alone when compared to 
surgery.  
Good local control can be achieved by radiation therapy alone as shown in these 
studies. Dose and dose per fraction schedule differs from institution to institution and the 
standard dose is usually a total of 70 Gy in 35 fractions, given five days per week. The 
local control rates using this dose prescription have been good in achieving local control 
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and delaying DFS. More studies have sought to achieve higher control rates by using 
higher dose per fraction. A higher dose per fraction can be used in these tumors owing to 
several factors. 
 Radiobiology explains that hypofractionation will lower the therapeutic ratio 
between tumors and late-responding normal tissues, compared with conventional 
fractionation, in the same overall time. This expectation depends on the α/β ratio for 
the tumor being considerably higher than for late-responding normal tissues; exceptions 
could therefore occur for tumors that have low α/β ratios, for example some melanomas, 
liposarcomas and potentially early-stage prostate and breast cancer. Hypofractionation is 
considered to be superior to conventional fractionation. 
Overall treatment time affects both acute effects and tumor control.  It is now well 
documented for head and neck cancer, that, local control is reduced by about 0.4 -2.5% 
for each day that overall treatment time is prolonged. Hypofractionation is 
advantageous in this regard as it administers the same dose (BED value of the dose 
or EQD2) to complete it in a shorter time period. The BED ( Biologically Effective 
Dose) for this dose regimen is calculated to be 77.17 Gy, which is slightly higher than the 
prescribed dose for the standard early stage glottic carcinoma, but is by no means lesser 
or inadequate compared to the former.  
Another factor to take into account is tumor repopulation. This is the 
phenomenon by which treatment with any cytotoxic agent, including radiation, can 
trigger surviving cells (clonogens) in a tumor to divide faster than before. This is known 
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as accelerated repopulation. During the time that the tumor is overtly shrinking and 
regressing, the surviving clonogen are dividing and increasing in number more rapidly 
than ever. Withers and colleagues surveyed the literature on radiotherapy for head and 
neck and estimated the dose to achieve local control in 50% of cases as a function of 
overall duration of fractionated treatment. The analysis suggests that clonogen 
repopulation in this human cancer accelerated at about 28 days after the initiation of 
radiotherapy in a fractionated regime. A dose increment of about 0.6 Gy per day is 
required to compensate for this repopulation. Such a dose increment is consistent with a 
4-day clonogen doubling rate, compared with a median of about 60 days for unperturbed 
growth. This problem of accelerated repopulation of the tumor clonogens is circumvented 
by a shorter treatment time duration and yet achieving the same tumoricidal dose to 
achieve excellent local control. 
Another reason for the feasibility of hypofractionated radiation therapy in early 
glottic cancer is due to the fact that squamous cell carcinoma of the glottis is usually 
well differentiated and a slowly growing lesion.  
In a study done by Krzysztof Skladowski et al., the dose along with the overall 
treatment time was established. They also took into account the pretreatment hemoglobin 
level of the patient. In this study, 235 patients with T1N0M0 glottic cancer were recruited 
and treated by radiation therapy alone given in a conventional schedule with 5 fractions 
each week. The individual total dose, dose per fraction, and overall treatment time (OTT) 
ranged from 51–70 Gy, 1.5–3.0 Gy, and 24–79 days, respectively. The median follow-up 
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was 48 months. Patient data—total dose, dose per fraction, Overall Treatment Time and 
hemoglobin level (Hb) measured before the radiation treatment—were fitted by the 
mixed LQ/log-logistic model. They concluded that the dose–response curve for 235 
patients with T1 glottic cancer was well defined and steep, and showed significant 
decrease in tumor control probability (TCP) when total doses were below 61 Gy. The 10-
day prolongation of OTT, from 45 to 55 days, decreased the TCP by 13%. The dose of 
0.35 Gy/day, compensated repopulation during the 1 day of prolongation, which indicates 
a potential doubling time (Tpot) for glottic T1 tumor clonogens of 5.5 days. The drop 
of Hb level of 1 g/dl (from 13.8 g/dl to 12.8 g/dl) gave a 6% decrease of TCP, provided 
that OTT was 45 days. Therefore, dose per fraction, above 2Gy and overall treatment 
time to around 6 weeks proves to be a schedule where acceptable tumor control is 
achieved. 
 
In another study where growth rate of laryngeal cancer was studied, there was a 
variable range of the rate of growth. The rate of tumor growth seemed to be an 
important factor for Disease Free Survival and Overall Survival. This tumor growth 
rate is independent of age, differentiation and tumor volume associated with DFS, but N-
stage seems to be a more important risk factor.  There are sparse lymphatics in the 
laryngeal glottis, hence, the major risk factor can be taken into less consideration when 
analyzing the factors that affect  the growth rate of the tumor, which in turn, affect the 
DFS and OS. This study showed that tumors that grow rapidly had a worse outcome in 
the form of decreased DFS and that slow growing tumors shows better DFS and OS. This 
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pertains to slowly growing early stage glottic cancers which are slow growing and are 
amenable to fractions sizes above 2.0 Gy i.e., the standard dose per fraction. 
Other studies that have shown increased benefit in terms of local control by using 
a dose higher than the standard fraction have been successful and have proven that 
hypofractionated radiation therapy is the preferred treatment in early stage glottic cancer. 
. This trial compared two arms- one that of conventional fractionation 66 Gy in 33 
fractions for T1 disease, 70 Gy in 35 fractions for T2 disease and a hypofractionation arm 
63 Gy in 28 fractions for T1 disease and 67.5 Gy in 30 fractions for T2 disease. All 
patients were followed up for 67 months and the primary objective was local progression 
free survival. The 5-year local progression free survival for the conventional arm was 
77.8% and 88.5% for the hypofractionated arm. There was no difference in toxicity in 
both the arms. This study established the fact that hypofractionation is not inferior to 
conventional radiation in terms of local control and toxicity. This method of treatment 
proved that hypofractionated radiotherapy can be given for early T1 and T2 lesions in 
carcinoma of glottis with advantages of potential better local control and shortened 
treatment time. 
  A Japanese study by Onimaru et al was done in 200 patients with T1-T2 glottic 
cancers to investigate the importance of the overall treatment time by giving 
hypofractionated radiation therapy 2.5 Gy per fraction for a total dose of 65 Gy, four 
fractions a week. It was found that patients who completed the treatment within 46 days 
had a significantly better local control (91.9±2%) than those who completed treatment in 
47 or more days ( 82.6±6%). 
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 Ermis et al conducted a retrospective analysis with hypofractionated radiotherapy 
with 55Gy in 20fractions at 2.75Gy per fraction in 132 patients. Five year local control 
and overall control rates were 85.6 % and 97.3 % respectively, with T1a  having  
91.8 %  and 100 %, T1b - 81.6 and 93.8 %, and T2 - 80.9 % and 95.8 %. Only one 
patient needed tracheostomy due to a non-functioning larynx while on long term follow 
up. This study concluded that hypofractionated radiation therapy for early stage glottic 
cancer shows high rates of local control with acceptable toxicity. 
 Another study from Japan done by Karasawa et al evaluated the effect of 
hypofractionated radiation therapy in 69 patients of early glottic cancer with  
2.25 Gy per fraction upto a total dose of 63 Gy treated within a median time of 41 days. 
One case of T2 glottic cancer could not reach complete response, but all other cases 
achieved complete response. The 5-year LC rates in larynx T1 and larynx T2 were 
97.6%,  and 70.1%, respectively. No acute adverse effects more than Grade 2 toxicity 
(CTCAE 3.0) were seen. They concluded that this treatment was safe and valuable in 
treating early glottic cancer, with T1 showing  a better outcome compared to historical 
data. For T2, local control did not show any improvement compared to historical data and 
treatment strategy that involves dose excalation is needed for these tumors. 
 Khan et al conducted a retrospective analysis to evaluate the patient, tumor and 
treatment characteristics in patients with early glottic carcinoma in 141 patients. Therapy 
consisted of 2.2 Gy per fraction for 25 fractions upto a total dose of 55 Gy within 5 
weeks with a 6 MV linear accelerator. The 5-year local control rates were as follows: 
T1a, 94%; T1b, 83%; T2a , 87%; T2b, 65%. The 10-year local control rates were as 
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follows: T1a, 89%;T1b, 83%; T2a, 87%; T2b, 56%.  This study highlighted the 
improvement in voice quality post radiation therapy in those patients who initially 
had poor voice quality. 73% out of the 92% of patients experienced an improvement, 
and none of the patients suffered severe or fatal complications. They concluded that 
definitive radiotherapy offered excellent local control in T1-T2a, N0 glottic carcinoma 
along with good voice preservation and minimal long term toxicity. T2b tumors had an 
inferior response and alternative strategies may be considered. 
 Mendenhall et al described a local control of 94%, 93%, 80%, 72% for T1a, T1b, 
T2a and T2b respectively for patients treated with 2-2.25 Gy per fraction, one fraction 
daily.  Out of the 519 patients received radiotherapy at the University of Florida 
(Gainesville, FL) for T1N0–T2N0 glottic carcinoma, six patients developed severe 
complications, including severe mucositis necessitating hospitalization and a treatment 
break ,  total laryngectomy for a suspected local tumor recurrence with a pathologically 
negative specimen, laryngeal edema, and a pharyngo-cutaneous fistula after a salvage 
total laryngectomy . Five of these patients had T2N0 disease. None of these patients died.  
 Laskar et al conducted a retrospective analysis to evaluate the effect of dose and 
fractionation with respect to tumor characteristics, toxicity and outcome in patients with 
T1N0 glottic cancer. The records of 652 patients were analyzed. The four 
hypofractionated schedules were 50 Gy in 15 fractions (3.3 Gy per fraction), 55 Gy in 16 
fractions (3.43 Gy per fraction), 60 Gy in 24 fractions (2.5 Gy per fraction) or 62.5 Gy in 
25 fractions (2.5 Gy per fraction). The patients were categorized into two groups of < 3 
Gy or > 3 Gy. All patients were treated with 6MV photons in linear accelerator. Local 
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control in 10 years was 84% and overall survival was 86.1% for T1 glottic 
carcinoma.. 
 Short et al conducted yet another study to analyze the effect of dose and 
fractionation compared to standard fractionation (SFX) in T1, T2 N0 tumors in glottic 
cancer. This New Zealand study employed Accelerated Hypofractionated Radiation 
Therapy (AHFX), with 145 patients receiving this treatment. The treatment consisted of 
60-66 Gy in 30-33 fractions (SFX) with 60 Co and 6 MV beams. AHFX consisted of 52.5-
55 Gy in 20 fractions over 4 weeks using 60 Co and 6 MV beams. The 5-year overall 
survival was 78%. The 5-year loco-regional control for T1was higher in AHFX compared 
to SFX. Locoregional control in T2 was similar in both fractionation schedules. None of 
the patients had grade 4 or 5 late reactions. These results showed that AHFX is 
comparable to standard fractionation regimen with equivalent local control and 
toxicity. 
 Spector et al evaluated the therapeutic outcome of dose on the voice quality and 
preservation in patients treated with low dose, high dose radiation therapy and surgery. 
This retrospective study analyzed 625 patients who were divided into four groups- low 
dose radiation- 55-65 Gy, in 1.5-1.8 Gy per fraction, high dose radiation with 65-70 Gy 
in 2-2.25 Gy per fraction daily. 404 patients underwent conservation surgery and 61 
underwent endoscopic resection. The overall local control was 89% and the overall 
unaided laryngeal voice preservation was 90%. Actuarial survival was significantly 
decreased in the low dose group was compared to the other groups. This study concluded 
that the four treatments used provide similar rates of survival and ultimate local control. 
 89 | P a g e  
 
The low dose arm was associated with lower actuarial overall survival and unaided voice 
preservation. Hence, the survival, local control and voice preservation rates were 
comparable in all groups except for low dose radiation group which showed a lower 
overall survival and unaided voice preservation. 
 Quynh-Thu X. Le et al performed a prospective study in the University of 
California to assess the significance of fraction size, total dose and overall treatment time 
in the control of T1-T2, N0 glottic carcinoma. A total of 398 patients were recruited and 
treatment was delivered in 5 days per week. Minimum tumor dose ranged from 46.6- 
77.6 Gy , with a median dose of 63 Gy. The fraction size was <1.8  Gy in 146 patients, 
1.8-1.99 Gy in 128, 2-2.24 Gy in 62 and 2.25 Gy in 62 patients. All patients were treated 
within a median of 50 days. 5 year control was 85% for T1 and 70% T2 glottic 
carcinomas. For the T1 lesions, there was no apparent relationship between the fraction 
size, overall time and total dose with respect to local control on multivariate analysis. 
 For T2 lesions, local control rate was 100% for the patients treated with 43 days overall 
time, 2.25 Gy per fraction. Local control was 44% for those treated with fractions size 
<1.8 Gy, 78% for those treated with a total >65 Gy. This study concluded that factors like 
total dose and overall treatment time were significant factors when considering the 
treatment and local control of T2 but not T1 glottic carcinomas. Anterior commisure 
involvement was also associated with lower local control rates for T1 but not T2 lesions.  
 
 Gowda et al. conducted a study in T1 glottic tumors with invasive squamous cell 
carcinoma. All patients were treated with definitive radiotherapy with a total tumor dose 
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of 50-52.5 Gy in 16 fractions over 21 days. The fraction size ranged from 3.12 to 3.28 
Gy. This study achieved 5-year local control rates of 93%; there were 14 recurrences 
of which seven were successfully salvaged by surgery, giving an ultimate local control 
of 96%. The 5-year overall survival was 80% and cause specific survival was 97% at 
5 years.  
  
SUBSET ANALYSIS 
Most of the patients were males, which might be due to the associated risk factors 
like smoking and alcohol. The response rate was also higher in males when compared to 
females. 
Well differentiated tumors showed a poorer response when compared to 
moderately or poorly differentiated tumors.  The results of this study showed poorly 
differentiated high CR > moderately > well differentiated histology. One patient with 
sarcomatoid histology showed poor response.  
The primary objective of this study was to determine the locoregional control as 
discussed above. As the sample size was small, statistical analysis is questionable for its 
significance. 
The secondary objective of this study is the toxicity assessment. Most of the 
patients had grade 1 or 2 skin reactions and mucositis. None of the patients required 
parenteral feeding or nasogastric tube feeding. None of the patients experienced grade 3 
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or 4 toxicity. There was one case of grade 1 laryngeal edema. The patient was treated 
conservatively and didn’t require hospitalization.  
There were no treatment related deaths in this study. 
MERITS OF THIS STUDY:  
 All patients had early stage glottic cancer squamous cell carcinoma, except 
one patient, and the treatment of choice is primary radiation therapy, was 
given. 
 Optimal tumoricidal dose of 63Gy in hypofractionated RT, BED value of 
77 Gy, was given for all patients. 
 Treatment time was shorter than the time taken by standard fractionation. 
 Toxicities were manageable. No treatment related death occurred in this 
study. Toxicity were graded with RTOG Acute radiation morbidity scoring 
criteria and CTCAE version 4.03 
 Response assessment was done after 4-6weeks of completion of radiation, 
RECIST 1.1 criteria was used for assessment. 
DEMERITS OF THIS STUDY: 
 There wasn’t long term follow up of this study, so progression free survival, 
overall survival could not be assessed. 
 Radiation delivery was given through 2D technique. 
 This is a single arm phase two trial, hence double armed study and randomized 
control trial must follow to determine prognostic significance and survival rates. 
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Future perspective:  
This study further established the feasibility and efficacy of radiation in early stage 
glottic cancer. Different fractionation protocol might be needed to compare with to 
achieve adequate BED/EQD2 , especially for T2 tumor control. Randomized trial using 
the same protocol is recommended. 
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CONCLUSION 
 Hypofractionated radiation therapy is valuable and feasible in the definitive 
treatment by radiotherapy and provides excellent LC and CSS for T1-T2, N0 glottic SCC, 
with excellent voice preservation outcomes and minimal long term toxicity. Dose fraction 
sizes above 2.25 Gy have shown excellent local control. For the long term analysis of this 
study, a longer follow up period is required. Dose fraction sizes of 3.12-3.28 Gy may be 
required for better local control of T2 tumors. There must be caution while using a large 
dose per fraction for the prevention of late toxicity in the form of cartilage necrosis or 
severe laryngeal edema.  A dose schedule of 55Gy in 20 fractions over 4 weeks offers 
high rates of local control with acceptable long term toxicity for both T1 and T2 disease. 
 Non-SCC histology might be less responsive to radiation therapy alone and dose 
escalation might be required for good local control. 
In general, definitive treatment with radiotherapy of dose per fraction above 2.0 
Gy is safe, beneficial and feasible for patients with early glottic cancer,  showing 
excellent local control rates along with preservation of voice quality and minimal 
toxicity. 
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APPENDIX 1 
TABLE NUMBER  TITLE  
1  Cancer trend  
2  Head and neck cancer Site (1)  
3  Head and neck cancer site (2)  
4  Age distribution of study population  
5  Gender distribution of study population  
6  ECOG performance status  
7  Habits/ addiction of the study population  
8  Symptoms / Signs  
9  Primary site  
10  Subsite analysis  
11  Tumor Tstage  
12  Stage grouping  
13              Histological differentiation  
 
14  Response results  
15  Site Vs response  
16  T stage Vs response  
17  Histological response Vs Response  
18  ECOG Vs Response  
19  Age Vs response  
20  Stage Vs response  
21  Treatment Vs response  
22  Acute Toxicity  
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APPENDIX 2 
FIGURE  TITLE  
1,2,3,4 Anatomy of larynx 
5  Lymph node incidence 
6  Age distribution of the study population 
7  Gender distribution of the study 
population 
8  ECOG performance status 
9  Symptoms and signs 
10  Site distribution of the study population 
11 Subsite Analysis 
12 T stage in the study population 
13  Nodal stage in the study population 
14  Stage grouping 
15  Treatment results – Response 
16  Site Vs Response 
17  T stage Vs Response 
18  Histologic differentiation Vs Response 
19  Response in the Primary 
20 Acute toxicity 
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APPENDIX 3 
RTOG ACUTE RADIATION MORBIDITY CRITERIA 
SITE   GRADE 
0  
GRADE1  GRADE2  GRADE3   GRADE 4  
SKIN  No 
change 
over 
baseline   
Follicular, 
faint or dull 
erythema/ 
epilation/dry 
desquamation/ 
decreased  
sweating   
 
Tender or 
bright 
erythema, 
patchy moist 
desquamatio 
n/ moderate  
edema   
 
Confluent, 
moist 
desquamati 
on other 
than skin 
folds,  
pitting 
edema   
Ulceration, 
hemorrhage,  
necrosis   
 
Mucous 
Membran e   
 
No 
change 
over  
baseline   
 
Injection/ may 
experience 
mild  
pain not 
requiring  
analgesic   
 
Patchy 
mucositis 
which may 
produce an  
inflammator 
y 
serosanguinit 
is discharge/ 
may 
experience 
moderate 
pain 
requiring  
analgesia   
 
Confluent 
fibrinous 
mucositis/ 
may include 
severe pain 
requiring  
narcotic   
 
Ulceration, 
hemorrhage 
or necrosis   
 
 107 | P a g e  
 
SALIVARY  
GLAND   
 
No 
change 
over  
baseline   
 
Mild mouth 
dryness/ 
slightly 
thickened 
saliva/ may 
have slightly 
altered taste 
such as 
metallic taste/ 
these changes 
not reflected 
in alteration in 
baseline 
feeding 
behavior, such 
as increased 
use of liquids 
with meals  
Moderate to 
complete 
dryness/ 
thick, sticky 
saliva/  
markedly  
altered taste   
 
 Acute 
salivary 
gland  
necrosis   
 
Pharynx  
& 
Esophagu s   
No 
change 
over  
baseline   
 
Mild 
dysphagia or 
odynophagia/ 
may require 
topical 
anesthetic or 
non-narcotic 
analgesics/ 
may  
require soft 
diet   
 
Moderate 
dysphagia or 
odynophagia 
/ may 
require 
narcotic 
analgesics/ 
may require 
puree or  
liquid diet   
 
Severe 
dysphagia or 
odynophagia 
with 
dehydration 
or weight 
loss(>15% 
from 
pretreatment 
baseline) 
requiring   
N-G feeding 
tube, I.V. 
fluids or 
hyper  
alimentation   
 
 
Complete 
obstruction, 
ulceration, 
perforation,  
fistula   
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Laryngitis   
 
No 
change 
over  
baseline   
 
Mild or 
intermittent 
hoarseness/cou 
gh not 
requiring 
antitussive/ 
erythema of  
mucosa   
 
Persistent 
hoarseness 
but able to 
vocalize/ 
referred ear 
pain, sore 
throat, 
patchy 
fibrinous 
exudate or 
mild 
arytenoid 
edema not 
requiring 
narcotic/  
antitussive   
 
Whispered 
speech, 
throat pain 
or referred 
ear pain 
requiring 
narcotic/ 
confluent 
fibrinous 
exudate, 
marked 
arytenoid  
edema   
 
Marked 
dyspnea,  
stridor or 
hemoptysis 
with 
tracheosto 
my or 
intubation 
necessary   
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